{"id":"W4416507969","doi":"10.1182/bloodadvances.2025017083","title":"Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Hôpital Maisonneuve-Rosemont","funders":"Genentech; Servier; Astellas Pharma; Nippon Shinyaku; Incyte; BeiGene; Astex Pharmaceuticals; Celgene; Amgen; Ariad Pharmaceuticals; Ascentage Pharma; Jazz Pharmaceuticals; Teva Pharmaceutical Industries; Karyopharm Therapeutics; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Pfizer; Bristol-Myers Squibb","keywords":"Venetoclax; Cytarabine; Myeloid leukemia; Azacitidine; NPM1; Population; Chemotherapy; Chemotherapy regimen","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007086212,0.0002148064,0.0003139886,0.0003970312,0.0001718116,0.0004018222,0.0002082924,0.0002632097,0.0009724443],"category_scores_gemma":[0.002582201,0.00006537911,0.0002851999,0.0003899468,0.0001058805,0.0002223848,0.0002436054,0.0004589238,0.0001785437],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002681204,"about_ca_system_score_gemma":0.0002763307,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000698675,"about_ca_topic_score_gemma":0.001515495,"domain_scores_codex":[0.9996558,0.0001565446,0.00003195295,0.00006324055,0.00006152988,0.00003095469],"domain_scores_gemma":[0.9990797,0.0003949569,0.0002722441,0.0000604828,0.00007247747,0.000120109],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002984689,0.00006858025,0.9741061,0.00002458671,0.00008438404,0.00007748405,0.00004673748,0.001426905,0.0009609602,0.00008368273,0.0003514316,0.01978458],"study_design_scores_gemma":[0.0002198821,0.001720532,0.9402114,0.00005125297,0.000260262,0.0006332161,0.0001390946,0.05246388,0.001973815,0.0006848357,0.001621342,0.00002054185],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9986377,0.0002789805,0.0005228521,0.00006467234,0.000008375479,0.00001293393,0.0001633335,0.00000618209,0.0003049816],"genre_scores_gemma":[0.9990407,0.0000530882,0.0004611371,0.00001422212,0.000008812125,0.000006207394,0.0003400226,0.000001545222,0.00007434044],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0009724443,"threshold_uncertainty_score":0.003747582,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.005691558317478645,"score_gpt":0.2824183766750267,"score_spread":0.2767268183575481,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}